Finch raises £43m to advance microbiome-based therapies for recurrent CDI, Autism and other disease areas
The financing comes from new investors including OCV Partners, Susquehanna International Group (SIG), Symbiosis LLC and the Trans-Pacific Technology Fund, as well as existing investors, including Avenir Growth